Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Schwannomatosis: a genetic and epidemiological study.
Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, Lloyd SKW, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Freeman SR, Ealing J, Kellett M, Laitt R, Thomas O, Halliday D, Ferner R, Taylor A, Duff C, Harkness EF, Smith MJ. Evans DG, et al. Among authors: halliday d. J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1215-1219. doi: 10.1136/jnnp-2018-318538. Epub 2018 Jun 16. J Neurol Neurosurg Psychiatry. 2018. PMID: 29909380
Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J, Huson SM, Freeman SR, Lloyd S, Rutherford SA, King AT, Wallace AJ, Ramsden RT, Evans DG. Smith MJ, et al. Among authors: halliday d. J Med Genet. 2011 Apr;48(4):261-5. doi: 10.1136/jmg.2010.085241. Epub 2011 Jan 28. J Med Genet. 2011. PMID: 21278391
Genetic testing and screening of individuals at risk of NF2.
Evans DG, Raymond FL, Barwell JG, Halliday D. Evans DG, et al. Among authors: halliday d. Clin Genet. 2012 Nov;82(5):416-24. doi: 10.1111/j.1399-0004.2011.01816.x. Epub 2011 Dec 16. Clin Genet. 2012. PMID: 22098617
English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2.
Tysome JR, Axon PR, Donnelly NP, Evans DG, Ferner RE, O'Connor AF, Freeman SR, Gleeson M, Halliday D, Harris F, Jiang D, Kerr R, King A, Knight RD, Lloyd SK, Macfarlane R, Mannion R, Mawman D, O'Driscoll M, Parry A, Ramsden J, Ramsden R, Rutherford SA, Saeed SR, Thomas N, Vanat ZH. Tysome JR, et al. Among authors: halliday d. Otol Neurotol. 2013 Dec;34(9):1743-7. doi: 10.1097/MAO.0b013e3182a1a8b4. Otol Neurotol. 2013. PMID: 24136318
Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.
Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A, Raymond FL, Durie-Gair J, Hanemann CO, Hornigold R, Axon P, Golding JF. Ferner RE, et al. Among authors: halliday d. J Neurol. 2014 May;261(5):963-9. doi: 10.1007/s00415-014-7303-1. Epub 2014 Mar 12. J Neurol. 2014. PMID: 24619350 Free PMC article.
Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.
Smith MJ, Isidor B, Beetz C, Williams SG, Bhaskar SS, Richer W, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Fryer A, Rustad CF, Mills SJ, Samii A, du Plessis D, Halliday D, Barbarot S, Bourdeaut F, Newman WG, Evans DG. Smith MJ, et al. Among authors: halliday d. Neurology. 2015 Jan 13;84(2):141-7. doi: 10.1212/WNL.0000000000001129. Epub 2014 Dec 5. Neurology. 2015. PMID: 25480913 Free PMC article.
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT; English Specialist NF2 Research Group; Friedman JM, Evans DG. Hexter A, et al. Among authors: halliday d. J Med Genet. 2015 Oct;52(10):699-705. doi: 10.1136/jmedgenet-2015-103290. Epub 2015 Aug 14. J Med Genet. 2015. PMID: 26275417
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.
Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK; UK NF2 research group. Morris KA, et al. Among authors: halliday d. J Neurooncol. 2017 Jan;131(1):117-124. doi: 10.1007/s11060-016-2276-9. Epub 2016 Oct 28. J Neurooncol. 2017. PMID: 27796735
Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, Evans DG, Parry A. Halliday D, et al. J Med Genet. 2017 Oct;54(10):657-664. doi: 10.1136/jmedgenet-2017-104519. Epub 2017 Aug 28. J Med Genet. 2017. PMID: 28848060 Free PMC article.
Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient.
King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, Pathmanaban ON, Kellett M, Obholzer R, Afridi S, Axon P, Halliday D, Parry A, Thomas OM, Laitt RD, McCabe MG, Stivaros S, Erridge S, Evans DG; English Specialist NF2 research group. King AT, et al. Among authors: halliday d. Neurosurgery. 2018 Jul 1;83(1):38-42. doi: 10.1093/neuros/nyx368. Neurosurgery. 2018. PMID: 28973692
460 results